August 14, 2019

Cannassure Therapeutics appoints Dr. Yafit Stark to its Scientific Advisory Board

Cannassure Therapeutics announces the appointment of Dr. Yafit Stark, previous VP of Global Clinical Research in Teva’s Innovative R&D Division to Cannassure’s Scientific Advisory Board.

Dr. Stark established and managed the Global Clinical Research Departmnt and was a member of the leadership team of Teva’s Innovative R&D Division. Dr. Stark has over 30 years of experience in clinical development processes according to global and Israeli regulatory standards. In her senior positions at Teva, Dr. Stark led the clinical development of the company’s products, including Teva’s flagship product, Copaxone, for the treatment of Multiple Sclerosis.

Dr. Stark holds a PhD in Pathology from the Sackler School of Medicine, Tel Aviv University, and a Post-Doctorate in Immuno Histopathology.

Ran Amir, Cannassure’s CEO commented: “We are happy to welcome Dr. Yafit Stark as a member of Cannassure’s Scientific Advisory Board. During her career Dr. Stark promoted leading drugs, Copaxone and Azilect. We are confident that Dr. Stark’s vast knowledge and experience will significantly contribute to Cannassure’s entrance into the pharma world.”